Literature DB >> 18457871

WT1 protein expression in slowly proliferating myeloid leukemic cell lines is scarce throughout the cell cycle with a minimum in G0/G1 phase.

Gunter Kerst1, Nina Bergold, Susanne Viebahn, Friederike Gieseke, Marketa Kalinova, Jan Trka, Rupert Handgretinger, Ingo Müller.   

Abstract

Wilms' tumor gene 1 (WT1) is overexpressed in various hematological malignancies and has been proposed as a target for minimal residual disease (MRD) detection and for immunotherapy. Although WT1 is known as a key molecule for tumor cell proliferation, the expression pattern of WT1 in leukemic cells in dependency of proliferation has not yet been investigated. Furthermore, WT1 expression was mostly studied by reverse transcriptase PCR and the expression of WT1 protein has not been extensively studied. Here, we analyzed WT1 protein expression in the human myeloid leukemia cell lines K562 and HL-60 by indirect immunofluorescence and flow cytometry. Both cell lines exhibited varying nuclear WT1 immunoreactivity pointing to a cell cycle-dependent and/or proliferation-dependent WT1 expression. In rapidly proliferating cells high levels of WT1 protein were detected by flow cytometry. A reduced proliferation rate was associated with a low WT1 protein expression and an accumulation of cells in G(0)/G(1) phase. During G(0)/G(1) phase cells expressed WT1 at a lower level than in S or G(2)/M phase. Moreover, WT1 expression was diminished in all cell cycle phases in slowly proliferating cells. We conclude that WT1 protein expression is dependent on the cell cycle phase as well as on the proliferation rate. This finding might be relevant for MRD studies and immunotherapeutic strategies targeting WT1.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18457871     DOI: 10.1016/j.leukres.2008.03.006

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  5 in total

1.  miR-15a and miR-16-1 inhibit the proliferation of leukemic cells by down-regulating WT1 protein level.

Authors:  Shen-meng Gao; Chong-yun Xing; Chi-qi Chen; Si-si Lin; Pei-hong Dong; Fu-jun Yu
Journal:  J Exp Clin Cancer Res       Date:  2011-12-01

2.  Diagnostic value of Wilms tumor 1 and CD44 in Langerhans cell sarcoma: case series of 4 patients.

Authors:  Chang-song Wang; Yan-ping Chen; Wei-hua He; Jian Yin; Chun-fang Gao; Ping Wang; Hong Li; Xue-xia Lv
Journal:  Medicine (Baltimore)       Date:  2015-04       Impact factor: 1.889

3.  Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy.

Authors:  Willemijn van den Ancker; Jurjen M Ruben; Theresia M Westers; Dewi Wulandari; Hetty J Bontkes; Erik Hooijberg; Anita G M Stam; Saskia J A M Santegoets; Gert J Ossenkoppele; Tanja de Gruijl; Arjan van de Loosdrecht
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110

4.  Antileukemic Cell Proliferation of Active Compounds from Kaffir Lime (Citrus hystrix) Leaves.

Authors:  Songyot Anuchapreeda; Fah Chueahongthong; Natsima Viriyaadhammaa; Pawaret Panyajai; Riki Anzawa; Singkome Tima; Chadarat Ampasavate; Aroonchai Saiai; Methee Rungrojsakul; Toyonobu Usuki; Siriporn Okonogi
Journal:  Molecules       Date:  2020-03-12       Impact factor: 4.411

5.  Novel WT1 Target Genes: IL-2, IL-2RB, and IL-2RG Discovered during WT1 Silencing Using Lentiviral-Based RNAi in Myeloid Leukemia Cells.

Authors:  Duangnapa Dejjuy; Chavaboon Dechsukhum; Kovit Pattanapanyasat; Egarit Noulsri; Gregory A Dissen; Wilairat Leeanansaksiri
Journal:  Biomed Res Int       Date:  2020-10-14       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.